Sareum (LON:SAR) Issues Quarterly Earnings Results

Sareum (LON:SAR) posted its earnings results on Tuesday. The company reported GBX (0.90) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Sareum Price Performance

Shares of SAR traded up GBX 1 ($0.01) during trading hours on Thursday, hitting GBX 13 ($0.17). The stock had a trading volume of 976,388 shares, compared to its average volume of 420,953. The firm has a market capitalization of £16.23 million, a PE ratio of -3.08 and a beta of -1.08. Sareum has a 12 month low of GBX 10 ($0.13) and a 12 month high of GBX 52.50 ($0.68). The stock has a fifty day moving average price of GBX 17.82 and a 200 day moving average price of GBX 23.19.

Insider Buying and Selling at Sareum

In other Sareum news, insider Stephen Parker purchased 84,033 shares of Sareum stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). 5.02% of the stock is owned by corporate insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.